Phase 2 N=885 A Study of mRNA-1010 Seasonal Influenza Vaccine in Healthy Adults
Seasonal Influenza
Primary: Number of Participants With Solicited Local and Systemic ARs — 12; 43; 22; 16 Participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=60 Intensive Chemotherapy and Autotransplantation for Patients With Newly Diagnosed Anaplastic Oligodendroglioma
CNS Cancer · CNS BRAIN
Primary: Progession Free Survival — 85.7 % of participants without progression
Phase 2 N=9 Copper and Molybdenum Balance in Participants With Wilson Disease Treated With ALXN1840
Wilson Disease
Primary: Mean Daily Copper Balance: Day 1 Through Day 8 — 0.8025; 0.3062 milligrams/day
Phase 2 N=24 Phase II Study of Chemo-Radiotherapy in Patients With Resectable and Borderline Resectable Pancreatic Cancer
Pancreas Neoplasm Malignant Resectable
Primary: Frequency of R0 Resection — 11; 2 Participants
Phase 2 N=29 Platelet-Rich Plasma Therapy for Patellar Tendinopathy
Patellar Tendinitis
Primary: Change in Measure of Pain Level: VISA-P Score — 32.2; 46.3; 43.2; 52.5 score on a scale
Phase 2 N=225 Dexmedetomidine in the Treatment of Symptoms Of Acute Opioid Withdrawal
Opioid Withdrawal
Primary: Peak SOWS Scores at Baseline and Over Time — 3.6; 5.2; 6.0; 4.7 score on a scale
Phase 2 N=108 A Study to Assess the Safety and Efficacy of Oral Etrasimod in Adult Participants With Eosinophilic Esophagitis
Eosinophilic Esophagitis
Primary: Percent Change From Baseline in Esophageal Peak Eosinophil Count (PEC) at Week 16 — -58.4; -39.4; -21.5 Percent change — p=0.0103
Phase 2 N=76 An Early Bactericidal Activity, Safety and Tolerability of GSK3036656 in Subjects With Drug-sensitive Pulmonary Tuberculosis
Tuberculosis
Primary: Change in log10 Colony Forming Units (CFU) Per (/) Milliliter (mL) of Direct Respiratory Sputum Samples From Baseline to Day 14 — -0.199; -0.017; -0.092; -0.092…
Phase 2 N=234 Pharmacokinetics of MB-102 and Use of the Non-invasive Optical Renal Function Monitor (ORFM) Device in Subjects With Normal and Impaired Renal Function and a Range of Skin Color Types
Acute Kidney Injury
Primary: Number of Participants With Treatment-Emergent Adverse Events — 7; 7; 2; 1 Participants
Phase 2 N=83 A Study of CMV Vaccine (HB-101) in Kidney Transplant Patients
Cytomegalovirus (CMV) Infection · Kidney Transplantation
Primary: Number of Participants With Adverse Events and Serious Adverse Events — 6; 3; 23; 12 Participants
Phase 2 N=40 A Phase I/II GVHD Prevention Trial Combining Pacritinib With Sirolimus-Based Immune Suppression
Graft Vs Host Disease · GVHD
Primary: STAT Activity — 9.623 %pSTAT3+CD4+T cells at day +21
Phase 2 N=24 Study of Baricitinib, a JAK1/2 Inhibitor, in Chronic Graft-Versus-Host Disease After Allogeneic Hematopoietic Stem Cell Transplantation
Chronic Graft vs Host Disease · Chronic Graft-Versus-Host Disease
Primary: Phase 1: Number of Participants With Dose-Limiting Toxicities (DLT) — 0; 0 Participants
Phase 2 N=13 A Phase I/II Study of Ibrutinib in Previously Treated Epidermal Growth Factor Receptor (EGFR) Mutant Non-Small Cell Lung Cancer
Lung Cancer
Primary: Number of Participants With at Least One Dose Limiting Toxicity (DLT) Observed During the Dose Escalation to Determine the Maximum Tolerated Dose (MTD) — 0; 0 Participants
Phase 2 N=121 A Pilot Evaluation of BLI4900 Bowel Preparation in Adult Subjects
Colonoscopy
Primary: % of Subjects With Successful Bowel Preparation — 17; 37; 37; 16 Participants
Phase 2 N=55 Lenvatinib and Pembrolizumab in Differentiated Thyroid Cancers (DTC)
Columnar Cell Variant Thyroid Gland Papillary Carcinoma · Follicular Variant Thyroid Gland Papillary Carcinoma · Metastatic Thyroid Gland Follicular Carcinoma
Primary: Complete Response Rate (Cohort 1) — 0 percentage of participants